29027-72-3 Usage
Uses
Used in Pharmaceutical Research and Development:
4-AMINO-N-(2,3-DIMETHYLPHENYL)BENZAMIDE is used as a research compound for studying benzamide derivatives as potential drugs for various medical conditions. Its unique structure allows for the exploration of its therapeutic properties and potential applications in medicine.
Used in Organic Synthesis:
In the field of organic synthesis, 4-AMINO-N-(2,3-DIMETHYLPHENYL)BENZAMIDE serves as a valuable intermediate or building block for the synthesis of more complex organic molecules. Its presence of an amino and dimethylphenyl group provides versatility in chemical reactions and the formation of new compounds.
Used in Chemical Processes:
4-AMINO-N-(2,3-DIMETHYLPHENYL)BENZAMIDE may also have applications in various chemical processes, where its specific chemical properties can be utilized to achieve desired outcomes or to facilitate specific reactions.
It is important to handle and use 4-AMINO-N-(2,3-DIMETHYLPHENYL)BENZAMIDE according to proper safety protocols, as it may have potential hazards if not used appropriately.
Check Digit Verification of cas no
The CAS Registry Mumber 29027-72-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,9,0,2 and 7 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 29027-72:
(7*2)+(6*9)+(5*0)+(4*2)+(3*7)+(2*7)+(1*2)=113
113 % 10 = 3
So 29027-72-3 is a valid CAS Registry Number.
InChI:InChI=1/C15H16N2O/c1-10-4-3-5-14(11(10)2)17-15(18)12-6-8-13(16)9-7-12/h3-9H,16H2,1-2H3,(H,17,18)
29027-72-3Relevant academic research and scientific papers
Synthesis and evaluation of homofarnesoyl-substituted CAAX-peptidomimetics as farnesyltransferase inhibitors and antiproliferative agents
Schlitzer, Martin,Sattler, Isabel,Dahse, Hans-Martin
, p. 2037 - 2045 (2007/10/03)
Several CAAX-peptidomimetics were linked to homofarnesoic acid via a β-alanyl spacer with the intention to obtain a novel type of bisubstrate analogue farnesyltransferase inhibitors. However, the compounds were found to be only weakly active in the farnesyltransferase inhibition assay. Nevertheless, they displayed antiproliferative activity against different tumor cell lines in the low micromolar range. Replacement of the β-alanine moiety by aspartic acid-1-methyl ester resulted in a compound which inhibited the farnesyltransferase with an IC50 of 860 nM. The corresponding free acid showed a eightfold loss in activity (IC50 = 6.9 μM).
